The latest price target for Pulmonx (NASDAQ:LUNG) was reported by Stifel on October 31, 2024. The analyst firm set a price target for $16.00 expecting LUNG to rise to within 12 months (a possible 149.22% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Pulmonx (NASDAQ:LUNG) was provided by Stifel, and Pulmonx maintained their buy rating.

The last upgrade for Pulmonx Corp happened on February 27, 2023 when Wells Fargo raised their price target to $15. Wells Fargo previously had an equal-weight for Pulmonx Corp.

The last downgrade for Pulmonx Corp happened on February 23, 2024 when Wells Fargo changed their price target from $16 to $14 for Pulmonx Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pulmonx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pulmonx was filed on October 31, 2024 so you should expect the next rating to be made available sometime around October 31, 2025.

While ratings are subjective and will change, the latest Pulmonx (LUNG) rating was a maintained with a price target of $17.00 to $16.00. The current price Pulmonx (LUNG) is trading at is $6.42, which is out of the analyst’s predicted range.